NO960221L - 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner - Google Patents

9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner

Info

Publication number
NO960221L
NO960221L NO960221A NO960221A NO960221L NO 960221 L NO960221 L NO 960221L NO 960221 A NO960221 A NO 960221A NO 960221 A NO960221 A NO 960221A NO 960221 L NO960221 L NO 960221L
Authority
NO
Norway
Prior art keywords
substituted
alkoxyphenyl
purin
ones
drugs
Prior art date
Application number
NO960221A
Other languages
English (en)
Norwegian (no)
Other versions
NO960221D0 (no
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO960221D0 publication Critical patent/NO960221D0/no
Publication of NO960221L publication Critical patent/NO960221L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO960221A 1995-01-19 1996-01-18 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner NO960221L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (2)

Publication Number Publication Date
NO960221D0 NO960221D0 (no) 1996-01-18
NO960221L true NO960221L (no) 1996-07-22

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960221A NO960221L (no) 1995-01-19 1996-01-18 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner

Country Status (30)

Country Link
US (1) US5866571A (ja)
EP (1) EP0722943A1 (ja)
JP (1) JPH08231546A (ja)
KR (1) KR960029335A (ja)
CN (1) CN1138583A (ja)
AR (1) AR002704A1 (ja)
AU (1) AU4097796A (ja)
BG (1) BG61729B1 (ja)
BR (1) BR9600149A (ja)
CA (1) CA2167349A1 (ja)
CO (1) CO4700524A1 (ja)
CZ (1) CZ16896A3 (ja)
DE (1) DE19501480A1 (ja)
EE (1) EE9600020A (ja)
FI (1) FI960226A (ja)
HR (1) HRP960009A2 (ja)
HU (1) HUP9600107A3 (ja)
IL (1) IL116771A (ja)
MA (1) MA23779A1 (ja)
NO (1) NO960221L (ja)
NZ (1) NZ280829A (ja)
PE (1) PE10597A1 (ja)
PL (1) PL312353A1 (ja)
SG (1) SG47379A1 (ja)
SK (1) SK7696A3 (ja)
SV (1) SV1996000004A (ja)
TN (1) TNSN96005A1 (ja)
TR (1) TR199600701A2 (ja)
YU (1) YU2896A (ja)
ZA (1) ZA96399B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN1264843C (zh) * 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents

Also Published As

Publication number Publication date
MA23779A1 (fr) 1996-10-01
AR002704A1 (es) 1998-04-29
US5866571A (en) 1999-02-02
TNSN96005A1 (en) 2005-03-15
FI960226A (fi) 1996-07-20
YU2896A (sh) 1999-03-04
EP0722943A1 (de) 1996-07-24
JPH08231546A (ja) 1996-09-10
SG47379A1 (en) 1998-04-17
HRP960009A2 (en) 1997-12-31
CN1138583A (zh) 1996-12-25
KR960029335A (ko) 1996-08-17
CA2167349A1 (en) 1996-07-20
TR199600701A2 (tr) 1996-08-21
SK7696A3 (en) 1996-08-07
FI960226A0 (fi) 1996-01-17
CO4700524A1 (es) 1998-12-29
HUP9600107A3 (en) 1999-06-28
IL116771A (en) 1999-06-20
NO960221D0 (no) 1996-01-18
IL116771A0 (en) 1996-05-14
DE19501480A1 (de) 1996-07-25
PE10597A1 (es) 1997-06-13
NZ280829A (en) 1998-04-27
CZ16896A3 (en) 1996-08-14
EE9600020A (et) 1996-08-15
SV1996000004A (es) 1997-02-19
BG61729B1 (bg) 1998-04-30
AU4097796A (en) 1996-07-25
HU9600107D0 (en) 1996-03-28
BR9600149A (pt) 1998-01-06
HUP9600107A2 (en) 1997-05-28
ZA96399B (en) 1996-08-14
BG100291A (bg) 1996-07-31
PL312353A1 (en) 1996-07-22

Similar Documents

Publication Publication Date Title
NO960221L (no) 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
NO912151L (no) Essensiell-fettsyre-behandling.
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
BRPI0009719B8 (pt) processo de tratamento
DE69727142D1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
ITMI932571A0 (it) Estratti della cucurbita sp., procedimento per la loro produzione ed impiego nella medicina e nella cosmetica
EP1319402A4 (en) IgE FORMATION INHIBITORS
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
DK0808307T3 (da) Bicykliske isothiourinstofderivater, som kan anvendes ved terapi
FI952459A (fi) Amidoamiinien käyttö oftalmisissa koostumuksissa
EE200100188A (et) Optiliselt aktiivne püridüül-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
IE870577L (en) Topical amide preparation
AU2003229269A1 (en) Deposition method for endoprostheses provided for constantly administering medicaments
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
IT8519907A0 (it) Prodotto farmaceutico cosmetico, in particolare per la cura di acne e seborrea.
NO20012777D0 (no) Anvendelse av riluzol ved behandling av akustiske traumer
CA2238871A1 (en) Method of using beta-interferons to treat restenosis